Profil
Emmanuel Dulac worked as President & Chief Executive Officer at Zealand Pharma A from 2019 to 2022.
Prior to that, he was an Associate Director at Sanofi from 1994 to 2003, Vice President-Global Head Lung & Cystic Fibrosis at Novartis AG from 2006 to 2014, and SVP-Global Head Rare Disease Business Unit at Shire Plc from 2014 to 2016.
He also served as an Independent Director at Proteostasis Therapeutics, Inc. and Chief Commercial Officer & Senior Vice President at Alnylam Pharmaceuticals, Inc. Dr. Dulac holds a doctorate degree from Université de Paris XI Paris Sud and an MBA degree from ESSEC Business School.
Anciens postes connus de Emmanuel Dulac
| Sociétés | Poste | Fin |
|---|---|---|
| ZEALAND PHARMA A/S | Chief Executive Officer | 30/03/2022 |
| SHIRE | Corporate Officer/Principal | 01/08/2016 |
| NOVARTIS AG | Corporate Officer/Principal | 01/05/2014 |
| SANOFI | Corporate Officer/Principal | 01/08/2003 |
| PROTEOSTASIS THERAPEUTICS, INC. | Director/Board Member | - |
Formation de Emmanuel Dulac
| ESSEC Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| SANOFI | Health Technology |
| NOVARTIS AG | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Entreprise privées | 3 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
